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Abstract
Pancreatic cancer is considered a lethal and treatment-refractory disease. To obtain a potent anticancer drug, the cytotoxic
effect of 2-(benzo[d]oxazol-3(2H)-ylmethyl)- 5-((cyclohexylamino)methyl)benzene-1,4-diol, dihydrochloride (NSC48693) on
human pancreatic cancer cells CFPAC-1, MiaPaCa-2, and BxPC-3 was assessed in vitro. The proliferation of CFPAC-1,
MiaPaCa-2, and BxPC-3 is inhibited with IC50 value of 12.960.2, 20.660.3, and 6.260.6 mM at 48 h, respectively. This
discovery is followed with additional analysis to demonstrate that NSC48693 inhibition is due to induction of apoptosis,
including Annexin V staining, chromatins staining, and colony forming assays. It is further revealed that NSC48693 induces
the release of cytochrome c, reduces mitochondrial membrane potential, generates reactive oxygen species, and activates
caspase. These results collectively indicate that NSC48693 mainly induces apoptosis of CFPAC-1, MiaPaCa-2, and BxPC-3 cells
by the mitochondrial-mediated apoptotic pathway. Excitingly, the study highlights an encouraging inhibition effect that
human embryonic kidney (HEK-293) and liver (HL-7702) cells are more resistant to the antigrowth effect of NSC48693
compared to the three cancer cell lines. From this perspective, NSC48693 should help to open up a new opportunity for the
treatment of patients with pancreatic cancer.
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Introduction
Pancreatic cancer is considered an aggressive cancer since it
usually goes undetected until it reaches the late stage [1]. In
2010, pancreatic cancer was the 4
th most common cause of
cancer-related death across the world [2]. Treatment of patients
with pancreatic cancer mainly depends on surgery, radiation
therapy, chemotherapy or combined therapeutic methods. It is
well known that pancreatic cancer often has a poor prognosis
since the 80-85% of patients present at a locally advanced or
metastatic stage, precluding surgery, due to its high tendency for
local invasion and distant metastases. Chemotherapy can be
used to improve quality of life and gain a modest survival
benefit of pancreatic cancer. Single-agent gemcitabine approved
by FDA in 1998, represents currently the most effective
chemotherapeutic drug that improves the quality of life and
prolongs the life time of patients with advanced pancreatic
cancer for 5-week. Due to the occurrence of chemoresistance to
gemcitabine [3], gemcitabine-containing combinations, such as
gemcitabine-erlotinib, -placebo and -oxaliplatin, were invented
and exhibited synergistic effects and reduced resistance [4]. It is
regretful that little convincing results are found on clinically
relevant improvements in quality of life and survival. To address
this issue, there appears to be an urgent need for the
development of new anticancer drugs.
The understanding of the molecular mechanisms involved in
the development of pancreatic cancer has provided many hopes
for the discovery of new chemotherapeutical agents in pancreatic
cancer therapy [5]. The inhibition of apoptosis plays a vital role
in the deterioration process of pancreatic cancer like the other
tumors [6]. Apoptosis, or programmed cell death, is a highly
controlled physiological process and a core signaling pathway [7].
Thus, anticancer drugs as apoptotic inducer has been proposed
and widely accepted in the therapy of cancers [8]. Some works
have revealed that apoptotic-mediating therapy is a promising
horizon for the therapy in cancers with little toxicity to
surrounding normal cells due to their physiologically controlled
survival pathway [9,10]. The apoptosis-inducing therefore
continues to represent an important direction for the develop-
ment of new drugs for the treatment in patients with pancreatic
cancer.
In the present study, a potent lead termed as 2-(benzo[d]oxazol-
3(2H)- ylmethyl)- 5-((cyclohexylamino)methyl)benzene-1,4-diol,
dihydrochloride (NSC48693,Fig. 1) inhibits the proliferation of
pancreatic cancer cells CFPAC-1, MiaPaCa-2, and BxPC-3 by
inducing apoptosis in the mitochondrial-mediated pathway in vitro.
Excitingly, the cytotoxic effect of NSC48693 on cancer cells is
more pronounced than normal human embryonic kidney (HEK-
293) and liver (HL-7702) cells. These results support a role for
NSC48693 as a potent apoptotic inducer of pancreatic cancer.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37841Materials and Methods
Materials
All chemicals including Ac-DEVD-fmk (caspase-3 inhibitor) and
Ac-LEHD-fmk (caspase-9 inhibitor) were purchased from Sigma
(St Louis, MO), unless otherwise indicated. DMEM,IMDM and
fetal bovine serum (FBS) were purchased from Gibico (Grand
island, NY). The primary antibodies against caspase-3, caspase-8,
caspase-9, Bcl-2, Bax, cytochrome c and peroxidase-conjugated
goat antimouse or antirabbit secondary antibody as well as isotype
mouse IgG1, goat anti-mouse IgG1 FITC were purchased from
BD Bioscience (San Jose, CA). NSC48693 was kindly supplied
from NCI/DTP Open Chemical Repository (http://dtp.cancer.
gov). NSC48693 was dissolved in DMSO to make stock solution
(10 mg/mL) and diluted to various concentrations with double
distilled water containing 10% DMSO.
Background of NSC48693
The extensive studies on pancreatic cancer have identified that
Ras signaling is involved in the regulation of apoptosis. The
development of drugs targeting Ras and inducing apoptosis is
being pursued intensively in drug discovery. The active GTP-
bound Ras is in equilibrium with three distinct states, one of which
is the open non-signaling conformation that is a transient
intermediate during GTP hydrolysis [11]. This implies that the
Ras intermediate is a convergent point for survival signaling in
pancreatic cancer. At present, therefore, the open conformation
appears to be the most promising target for drug design. The
structure of GppNHp-bound RasG60A-GTP (PDB ID: 1XCM
[11]) was used in the docking calculations. All docking calculations
were performed by using the Autodock package [12]. The
database of National Cancer Institute (NCI) diversity set was used
for the virtual screening. We then ranked these small molecules
according to the predicted affinity and specificity defined [13]. 2-
(benzo[d]oxazol-3(2H)-ylmethyl)-5-((cyclohexyl- amino)-methyl)-
benzene-1,4-diol, dihydrochloride (NSC48693) picked out from
NCI database demonstrated growth inhibition effect on leukemia
cell lines CCRF-CEM and MOLT-4 as shown in NCI Cancer
Screen Current Data (http://dtp.nci.nih.gov). Little efforts focus
on the effect of NSC48693 on pancreatic cancer, thus it offers a
selected choice of high quality inducer of apoptosis.
Cell Culture
The human pancreatic cancer cell lines CFPAC-1, MiaPaCa-2,
and BxPC-3 were obtained from American Type Culture
Collection (ATCC, Rockville, MD) and cultured in DMEM and
IMDM medium supplemented with 10% FBS and antibiotics (100
units/mL penicillin and 100 mg/mL streptomycin sulfate), respec-
tively. The human embryonic kidney 293 (HEK-293) and liver
(HL-7702) cells were obtained from Chinese Academy of Science
Type Culture Collection (Shanghai, China) and incubated in
DMEM medium supplemented with 10% FBS. The cells were
detached from the monolayer using 0.25% trypsin and 0.53 mM
EDTA for 5 min at 37uC when the cells were grown to near
confluence.
Hoechst 33342 Staining
The three human pancreatic cancer cells (1610
5 cells/plate)
were respectively seeded onto 6-well glass-bottomed plate and
allowed to attach overnight. The cells cultured in 135 mL DMEM
medium were treated by using either 15 mL 250 mg/mL
NSC48693 (final concentration 25.0 mg/mL) as experimental
groups or 15 mL double distilled water containing 10% DMSO as
control groups, and then cultured for 48 h at 37uC and 5% CO2
conditions. Thereafter, the cells were fixed in MeOH–HOAc (3:1,
v/v) for 10 min at 4uC and then stained using Hoechst 33342 kit
(KeyGEN Biotech, Nanjing, China). The stained cells were
analyzed by confocal-laser scanning microscope (TCS SP2,
Heidelberg, Germany).
Cytotoxicity Assays
The cell viability of three pancreatic cancer cells and two
human normal cells (1610
4 cells/well in 96-well plate) after being
treated by double distilled water containing 10% DMSO as
control groups or various concentrations of NSC48693 as
experimental groups was assessed by thiazolyl blue tetrazolium
bromide (MTT) assay. The cells were treated for 48 h and then
the optical density (OD) at 490 nm was read with a 96-well
multiscanner autoreader (Biotech Instruments, New York). MTT
does not interfere with NSC48693 and causes a positive response.
Soft Agar Assays
Soft agar assays were performed essentially as previously
described [14]. The single cell suspensions of pancreatic cancer
cells containing 1610
4 cells in 0.3% agar were placed in 3.5 cm
dishes on top of a gelled layer of 1% agar in medium (DMEM or
IMDM with 10% FBS) and cultured with double distilled water
containing 10% DMSO as control groups or various concentra-
tions of NSC48693 as experimental groups at 37uC. Colonies were
fixed with 2.5% glutaraldehyde and counted scoring only the
colonies that were larger than 10 cells in diameter under Olympus
X71 inverted phase microscope (Dr. Schumann Optik OHG,
Hessen, Germany). Percentage of colony forming efficiency was
calculated as the number of colonies/100 seeded cells.
Apoptosis Assays
The apoptosis of three pancreatic cancer cells (1610
6 cells/well
in 24-well plate) after being treated by double distilled water
containing 10% DMSO as control groups or various concentra-
tions of NSC48693 as experimental groups was measured by
Annexin V-FITC/propidium iodide (PI) apoptosis detection kit
(KeyGEN Biotech, Nanjing, China). The quantification of PI and
FITC signals was performed using fluorescence activated cell
sorter FACSAria (BD Bioscience, San Jose, CA) and percentage of
stained cells in each quadrant was quantified using Diva 6.0
software (BD Bioscience, San Jose, CA). In total, 10,000 events
were analyzed in each sample.
Caspase Activity Assay
Cells were cultured in 6-well plate (5% CO2,3 7 uC) at seeding
density of 2610
6 cells/well. Plates were preincubated overnight
before the solutions of drug were added to each well. After a
period of exposure (24 or 48 h) with various concentrations
NSC48693, cells harvested by trypsinization with trypsin/EDTA
solution were washed by PBS solution and the activity of caspase-
3, caspase-8, and caspase-9 was determined by caspase activity
Figure 1. The structure of NSC48693.
doi:10.1371/journal.pone.0037841.g001
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DEVDase, IETDase, and LEHDase activity was measured by
measuring proteolytic cleavage of chromogenic substrates Ac-
DEVD-pNA, Ac-IETD-pNA, and Ac-LEHDpNA, which were
used as the substrates for caspase-3, caspase-8, and caspase-9-like
proteases, respectively [15]. The absorbance of enzymatically-
released pNA was measured at 490 nm on a multiscanner
autoreader.
Analysis of Cytochrome c Release
Cells were cultured in 24-well plate (5% CO2,3 7 uC) at seeding
density of 5610
4 cells/well. Plates were preincubated overnight
before the solutions of drug were added to each well. After a
period of exposure (6 or 12 h) with various concentrations
NSC48693, cells were harvested by trypsinization with trypsin/
EDTA solution and washed with Hanks balanced salt solution
supplemented with 2% bovine serum albumin and 0.2% azide.
Thereafter, cells were fixed and permeabilized using Cytofix/
Cytoperm kit (BD Bioscience, San Jose, CA). Unspecific binding of
anti-cytochrome c antibody was blocked with mouse IgG1. Anti-
cytochrome c (7H8.2C12) was added for additional 30 min at 4uC.
Then, the cells were incubated with goat anti-mouse IgG1 FITC
(1:20) for 30 min at 4uC. After washing with Perm/Wash solution,
cells were immediately analyzed by flow cytometry (FCM).
Totally, 10,000 events per sample were acquired and analyzed.
Measurement of the Mitochondria Membrane Potential
(DYm)
Changes in DYm were measured by Rhodamine-123 (Rho-123)
dye [16]. Cells were cultured in 24-well plate (5% CO2, 37uC) at
seeding density of 5610
4 cells/well. Plates were preincubated
overnight before the solutions of drug were added to each well.
After a period of exposure (48 h) with various concentrations
NSC48693, cells harvested by trypsinization with trypsin/EDTA
solution were washed by PBS solution and incubated with Rho-
123 (10 mg/mL). Thereafter, Rho-123 fluorescence was measured
by FCM. The percentage of Rho-123- cells represents the effective
collapsed DYm; the reduction of Rho-123 indicates the loss of
DYm in cells [16]. In total, 10,000 events were analyzed in each
sample.
Figure 2. NSC48693 induces morphological alterations in CFPAC-1, MiaPaCa-2, and BxPC-3 cells. After 24 h adherence, the cells (1610
5
cells/plate) were treated with 25.0 mg/mL of NSC48693 for 48 h. Then, cells were examined using confocal laser scanning microscopy.
doi:10.1371/journal.pone.0037841.g002
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Flow cytometric detection of ROS was performed as described
previously [17]. Briefly, cells were cultured in 24-well plate (5%
CO2,3 7 uC) at seeding density of 5610
4 cells/well. Plates were
preincubated overnight before the solutions of drug were added to
each well. After a period of exposure (2 h) with various
concentrations NSC48693, cells were harvested by trypsinization
with trypsin/EDTA solution and subsequently ROS fluorescence
intensity was determined by FCM. ROS levels were expressed as
percentage, which was calculated by Diva 6.0 software. In total,
10,000 events were analyzed in each sample.
Western Blotting
The cells (2610
6 cells) were seed to 10 cm plate and cultured in
the incubator overnight. Then the cells were exposed with 1 or 26
IC50 concentration of NSC48693 and 10% DMSO (control) for
24 h. Whole-cell proteins and mitochondrial fractions were
isolated by using the protein extraction kit (KeyGEN Biotech,
Nanjing, China). The protein concentrations were determined
using BCA protein assay kit (KeyGEN Biotech, Nanjing, China).
Equal amounts of proteins were fractionated using 12% SDS-
PAGE and then transferred to the polyvinylidene difluoride
(PVDF) membranes. The membranes were incubated with
primary antibodies against caspase-3, caspase-8, caspase-9, cyto-
chrome c, Bcl-2, and Bax, after being blocked with 3% BSA in
TBS. The membranes were incubated with peroxidase-conjugated
goat antimouse or antirabbit secondary antibody. Actin was used
for the control loading. In the inhibition assay for caspase-3 and
caspase-9, the cells were pretreated by 20 mM Ac-DEVD-fmk or
Ac -LEHD-fmk for 2 h after adherence, and the medium was
changed by the culture containing 26 IC50 concentration of
NSC48693 or 10% DMSO.
Statistical Analysis
All data were expressed as means 6 SD of triplicate
experiments, and reproducibility was confirmed in at least three
separate experiments. Statistical analysis was done using SPSS
11.5 statistical software.
Results
NSC48693 Changes Cell Morphology
Cellular morphology can be used as a parameter for measuring
the effect of a compound on cell toxicity. Since the nuclear
condensation occurs in this stage of apoptosis, the apoptotic
morphology of the nucleus will be evident upon staining [18]. The
nuclear staining with Hoechst 33342 shows that the cells in control
groups are proportional and well distributed (Fig. 2). As compared
with the normal nuclear morphology, typical morphological
changes, including cytoskeletal collapse, the formation of apoptotic
bodies and nuclear fragmentation, are observed in the treated cells
as shown with arrows in Fig. 2. These characteristics consistently
occurred during this form of cell death, which were all the
common characters of cell death [19].
NSC48693 Inhibits Cell Proliferation
In addition to detailed comparative analysis of the morpholog-
ical changes, the cytotoxicity of NSC48693 to cells was detected
Figure 3. NSC48693 inhibits the proliferation of CFPAC-1,
MiaPaCa-2, and BxPC-3 cells. After 24 h adherence, the cells (1610
4
cells/well in 96-well plate or 1 610
4 cells in 3.5 cm dish) were treated
with various concentrations of NSC48693 as indicated for 48 h. Then,
the growth inhibition was assessed by MTT method (A) and anchorage
independent growth assays (B), respectively. Each value represents
mean 6 SD in three independent experiments.
doi:10.1371/journal.pone.0037841.g003
Figure 4. The cytotoxic effect of NSC48693 on normal HEK-293
and HL-7702 cells. After 24 h adherence, the cells (1610
4 cells/well in
96-well plate) were treated with different concentrations of NSC48693
as indicated for 48 h. Then, the growth inhibition assays were assessed
by MTT method. Each value represents mean 6 SD in three
independent experiments.
doi:10.1371/journal.pone.0037841.g004
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in Fig. 3A, the viability of cancer cells is significantly decreased by
NSC48693 with the exposure dose increased. NSC48693 inhibits
cancer cells proliferation with IC50 value of 12.960.2 mM for
CFPAC-1, 20.660.3 mM for MiaPaCa-2, and 6.260.6 mM for
BxPC-3 at 48 h, respectively. This was further supported by the
ability of NSC48693 to block the anchorage-independent growth
of cancer cells in soft agar. When compared with control groups,
cancer cells form smaller and fewer colonies when grown in the
presence of NSC48693. As indicated in Fig. 3B, this response
occurs in a dose-dependent manner. Combined with the results,
we conclude that NSC48693 decreases the proliferation of cancer
cells in a dose-dependent manner.
Cytotoxic Effects of NSC48693 on HEK-293 and HL-7702
As showed in Fig. 4, the cell viability of HEK-293 and HL-7702
is 63.464.1% and 91.262.9% at a dose of 25.0 mg/mL of
NSC48693, respectively. NSC48693 inhibits HEK-293 and HL-
7702 cells proliferation with an IC50 value 144.568.8 mM and
198.6611.3 mM at 48 h, respectively. Obviously, the cytotoxic
effects of NSC48693 on normal human cells are less sensitive than
cancer cells CFPAC-1, MiaPaCa-2, and BxPC-3 as compared to
Fig. 3.
NSC48693 Induces Apoptosis
To rule out the possibility that inhibition of cell growth was due
to cytotoxic effects, apoptosis assay was performed. Cells positive
for Annexin V-FITC and negative for PI are in early stage of
apoptosis as shown in Q4 quadrant, while cells positive for both
Annexin V-FITC and PI are in the late stage of apoptosis or
necrosis as shown in Q2 quadrant [21]. Thus, the degree of
apoptosis correlated with the amount of positive Annexin V-FITC
cells. And the intact membrane integrity assessed by negative PI
staining suggests that apoptosis but not necrosis is the character of
apoptosis. As shown in Fig. 5, there is little binding of Annexin V-
FITC to the control cells, while the binding after treatment with
NSC48693 is increased as shown in Q4 quadrant. As for
MiaPaCa-2 cells treated at the concentration of 25.0 mg/mL of
NSC48693, the binding is increased from 73.161.0% to
82.762.8% at 24 h and 48 h. The binding is increased from
37.162.0% to 50.563.1% at 24 h and 48 h, after CFPAC-1 cells
are treated by 12.5 mg/mL of NSC48693. While the binding is
increased from 46.462.4% to 55.061.1% at 24 h and 48 h, after
Figure 5. NSC48693 induces apoptosis in CFPAC-1, MiaPaCa-2, and BxPC-3 cells. Extent of apoptosis induced in cancer cells (1610
6 cells/
well in 24-well plate) treated by 25.0 mg/mL of NSC48693 in MiaPaCa-2, 12.5 mg/mL of NSC48693 in CFPAC-1, and 6.25 mg/mL of NSC48693 in BxPC-3
for 24 or 48 h was measured by FCM, respectively. Representative results from three independent experiments are shown; and each value represents
mean 6 SD in three independent experiments.
doi:10.1371/journal.pone.0037841.g005
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with these observations, it is clear that the effect of NSC48693 on
cancer cells is primarily mediated by inducing apoptotic cell death.
Activation of Caspase
As major mediators of apoptosis, the activation of caspase
depends on proteolytic cleavage of the procaspase. To better our
Figure 6. Effect of NSC48693 on the activation of caspase-3, caspase-8, and caspase-9 in CFPAC-1, MiaPaCa-2, and BxPC-3 cells.
Cells (2610
6 cells/well in 6-well plate) were treated with NSC48693 at the indicated concentrations for 24 (A, B, C) or 48 h (D, E, F) then examined.
Each value represents mean 6 SD in three independent experiments.
doi:10.1371/journal.pone.0037841.g006
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induced apoptosis in cancer cells, we examined enzyme activities
of caspases with a spectrofluorometric assay using their corre-
sponding substrates [22]. As shown in Fig. 6A, C, D, F, the activity
of caspase-3 and caspase-9 is increased in a dose-and time-
dependent manner compared with untreated cells in three cancer
cells; the activity of caspase-8 linked to the death receptors fails to
be increased in CFPAC-1 and BxPC-3 cells (Fig. 6B, E). However,
the activity of caspase-8 in MiaPaCa-2 cells is increased in a dose-
and time-dependent manner compared with untreated cells. These
findings imply that NSC48693 activates the intrinsic mitochon-
dria-mediated apoptotic pathway leading to caspase activation to
induce apoptosis in CFPAC-1 and BxPC-3 cells. For MiaPaCa-2
cells, NSC48693 activates both the mitochondrial and membrane
death receptor apoptotic pathway.
Release of cytochrome c
The release of cytochrome c is a crucial step controlling the
apoptosome pathway. Clone 7H8.2C12 has been chosen to
specially detect intracellular cytochrome c. Therefore, the reduc-
tion in cytochrome c signal detected by antibody 7H8.2C12
reflects mitochondrial cytochrome c release and early-onset of
apoptosis [23]. As shown in Fig. 7, BxPC-3 cells in control groups
have low level of cytochrome c (11.861.7%), whereas NSC48693
treatment enhances mitochondrial cytochrome c release from
32.961.3% to 36.961.4% at the concentrations of 25.0 and
50.0 mg/mL for 6 h. CFPAC-1 cells untreated by NSC48693 have
normal mitochondrial cytochrome c level (7.961.9%), while the
mitochondrial cytochrome c release levels are increased from
35.961.2% to 47.660.6.9% at the concentrations of 25.0 and
50.0 mg/mL for 6 h. Also, MiaPaCa-2 cells treated by NSC48693
have an enhanced mitochondrial cytochrome c release from
4.661.8% in the control group to 19.061.3% and 29.362.8% at
the concentration of 25.0 and 50.0 mg/mL for 12 h, respectively.
Loss of DYm
DYm can be produced when protons were pumped from the
mitochondrial matrix to the inter-mitochondrial space [24]. And
the dissipation of DYm has been linked to some apoptotic
pathways, including mitochondrial apoptotic pathway [25].
Absolutely most untreated cells have intact plasma membrane
and normal DYm, however, the loss of DYm exhibits a dose-
dependent increase manner after cells were treated with
NSC48693 at 12.5 and 25.0 mg/mL for 48 h (Fig. 8). After
MiaPaCa-2 cells being treated with NSC48693, the percentage of
DYm collapse reaches 13.361.9% and 24.761.8%, respectively.
And the percentage of DYm collapse of CFPAC-1 cells reaches
18.961.1% and 34.262.9%, respectively. While the percentage of
DYm collapse in BxPC-3 cells is obvious and reaches 24.962.4%
and 92.968.9%, respectively. The experiments provide a suffi-
ciently accurate basis for the conclusion that cancer cells treated by
NSC48693 lose DYm.
Generation of ROS
The generation of ROS is directly related to mitochondria [16].
As demonstrated in Fig. 9, flow cytometric analysis reveals that
MiaPaCa-2 cells untreated have low level of endogenous ROS
Figure 7. Analysis of mitochondrial cytochrome c release. The cells (5610
4 cells/well in 24-well plate) were treated at the indicated doses for 6
(CFPAC-1 and BxPC-3) or 12 h (MiaPaCa-2). Intracellular cytochrome c was detected by antibody 7H8.2C12 in fixed and permeabilzed cells.
Percentages represent the proportion of cells with lowered cytochrome c signal. Representative results from three independent experiments are
shown; and each value represents mean 6 SD in three independent experiments.
doi:10.1371/journal.pone.0037841.g007
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ly intracellular ROS levels from 58.062.3% to 68.064.4% at the
concentrations of 50.0 and 100.0 mg/mL for 2 h. CFPAC-1 cells
untreated by NSC48693 have normal endogenous ROS level
(2.561.6%), while the ROS levels are increased from 74.062.8%
to 81.460.5% at the concentrations of 12.5 and 25.0 mg/mL for 2
h. Also, the ROS levels are increased from 9.861.3% to
16.462.7% after BxPC-3 cells are treated by NSC48693 at the
concentrations of 25.0 and 50.0 mg/mL for 2 h.
Effect of NSC48693 on Apoptosis-Related Proteins
The effect of NSC48693 on apoptosis-related proteins was
confirmed by western blotting as shown in Fig. 10. NSC48693
treatment increased the cleavage of caspase-9 and caspase-3 in a
dose-dependent manner. The expression of cleaved-caspase-8 was
almost undetectable in CFPAC-1 and BxPC-3 cells. However, the
cleavage of caspase-8 was obvious in MiaPaCa-2 cells, which was
agreement with the caspase activity as shown in Fig. 6. Simulta-
neously, the Bcl-2 protein expression was down regulated and Bax
was up regulated. The cytochrome c in cytosol was enhanced
concomitant with the related attenuation of cytochrome c in
mitochondria. In addition, the specific inhibitors of caspase-9 and
caspase-3 almost completely abolished the NSC48693-induced
cleavage of caspase-9 and caspase-3, respectively (Fig. 11).
Discussion
Although the uncovered chemotherapeutic drugs have yet to
achieve any real progress in clinical therapy so far, the
chemotherapy is still a backbone in the treatment of advanced
pancreatic cancer at present [25]. Thus, novel chemotherapeutic
drugs with different modes of action are always in need for the
treatment of pancreatic cancer patients. The mechanism of cell
death induced by chemotherapeutic drugs is thought to be an
endogenous apoptotic mechanism. Thus the induction of apop-
tosis in cancer cells has been recognized as an innovative drug
discovery strategy for cancer therapy [26–28].
Potential apoptotic inducers should kill cancer cells instead of
causing excessive toxicity to normal ones. In the present study, we
focused on evaluating the effect of NSC48693 on the death by
inducing apoptosis of human pancreatic cancer cells CFPAC-1,
MiaPaCa-2, and BxPC-3 in vitro. It appears that cancerous and
normal cells react differently to NSC48693 exposure in MTT
assays. The results of cell viability indicate that the viability of
cancer cells is significantly inhibited by NSC48693 with IC50 of
12.960.2 mM for CFPAC-1, 20.660.3 mM for MiaPaCa-2, and
6.260.6 mM for BxPC-3, respectively. However, the sensitivity of
normal cells to NSC48693 is considerably different. In contrast, no
obvious cytotoxicity is detected in normal cells with IC50
144.568.8 mM for HEK-293 and 198.6611.3 mM for HL-7702,
respectively. These results provide direct evidence that normal
cells HEK-293 and HL-7702 are more resistant to the anti-growth
effects of NSC48693 compared to the cancer cells CFPAC-1,
MiaPaCa-2, and BxPC-3. Based on the growth inhibitory effect
caused by NSC48693 on cancer cells as shown in Fig. 3, the cell
apoptosis in response to NSC48693 was investigated. Fig. 5
suggests that NSC48693 triggers the apoptotic cell death of
pancreatic cancer cells, which implies that NSC48693 has higher
Figure 8. Analysis of the loss of DYm. The cells (5610
4 cells/well in 24-well plate) were treated at the indicated doses for 48 h. Then the
experiments were subject to FCM. Representative results from three independent experiments are shown; and each value represents mean 6 SD in
three independent experiments.
doi:10.1371/journal.pone.0037841.g008
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4 cells/well in 24-well plate) were treated at the indicated doses for 2 h. Then the
experiments were subject to FCM. Representative results from three independent experiments are shown; and each value represents mean 6 SD in
three independent experiments.
doi:10.1371/journal.pone.0037841.g009
Figure 10. Immunoblots of whole-cell protein extracts after exposure to vehicle or to 1 or 26IC50 compound concentration for 24 h
in CFPAC-1, MiaPaCa-2, and BxPC-3 cells. Equal amounts of cellular proteins were fractionated on 12% SDS-PAGE gels and transferred to PVDF
membranes. Actin was used to control loading.
doi:10.1371/journal.pone.0037841.g010
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cells. Moreover, different cell types vary profoundly in their
susceptibility to apoptosis induction, which leas to distinct cellular
thresholds existing for apoptosis induction [29]. The critical issue
is surrounding normal tissues or cells may pause and repair the
damage while tumor cells die through apoptosis. NSC48693
appears to be less toxic to normal cell lines, which may attribute to
this possibility that normal cells have some protective mechanisms
against NSC48693 [30]. During the normal cellular reduction,
hydrogen peroxide generates and hydroxyl radical occurs. These
can be lost through uncoupling or driven off, leading to oxidative
damage. The normal cells have protective mechanisms to detoxify
excessive ROS, leading to the reduction of the toxic effect of
NSC48693 on HEK-293 and HL-7702.
Apoptosis can be triggered by several stimuli, and mitochondria
are considered to play a central role in both caspase-dependent
and caspase-independent apoptosis [31]. Mitochondria initiate
two distinct apoptosis pathways, namely the intrinsic mitochon-
drial pathway and extrinsic membrane death receptor pathway
[32]. For the major of chemotherapeutic drugs, apoptosis is
initiated by the intrinsic mitochondrial pathway [27,28]. Thus,
understanding the regulation of the intrinsic mitochondrial
apoptotic pathway is important for developing new inducer of
apoptosis and verifying the induction of apoptosis. Many pro-
death stimuli converge on the mitochondrial pathway during
apoptosis, which leads to permeabilization of the outer mitochon-
drial membrane and the release of proteins resided in the
mitochondrial inter membrane space. Cytochrome c, a kind of
soluble apoptosis signaling molecules, localized in the mitochon-
drial intermembrane space is released into the cytosol upon
apoptosis induction as shown in Fig. 7 and Fig. 10. The
cytochrome c release from the cells is an apoptosis-specific process
after induction of apoptosis, but not during necrosis [33].
Loss of DYm was observed under NSC48693 treatment as a
dose-dependent manner, suggesting that mitochondria are affected
particularly early during the apoptotic process. In the process of
apoptosis, mitochondria are a source of ROS generated by the
reduced DYm [34]. And the enhancement of ROS production has
long been related to the apoptotic response induced by anti-cancer
agents [35]. The relationship between ROS and the potency
inducing apoptosis in NSC48693-induced cancer cells as shown in
Fig. 9 indicates that NSC48693 elevates intracellular ROS levels.
To dissect the apoptotic cascade initiated by NSC48693-
induced dissipation of DYm, the proteolytic activity of caspase-3
and caspase-9 that is a marker for the mitochondrial pathway of
apoptosis was quantified. The dissipation of DYm activated
downstream effectors caspase-3 and caspase-9, with an increase in
a dose- and time-dependent manner (Fig. 6A, C, D, F). The little
up-regulation of caspase-8 activity other than MiaPaCa-2 as
shown in Fig. 6B, E ruled out the possible participation of death
receptors [36]. Rather, these observations confirmed that the
process of dissipation of DYm was essential for the initiation and
activation of downstream events with caspase-3 and caspase-9
culminated in apoptotic cell death [37]. These results implied that
ROS release in the presence of caspase activation was sufficient for
effective apoptosis of cancer cells.
Together with the data detailed in this study, several lines of
evidence suggest that NSC48693 works as an agent inducing
apoptosis in cancer cells by mainly activating the mitochondrial-
mediated apoptotic pathway. With more follow-up experiments,
therefore, studies on the molecular mechanisms of NSC48693
action should help to shed light on the treatment of pancreatic
cancer.
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